The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...

Switching to a long-acting cabotegravir/rilpivirine antiretroviral regimen may be safe for patients with HIV who have prior hepatitis B virus exposure, a real-world study shows.

† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...

Switching to long-acting CAB/RPV was not linked to HBV reactivation or incident infection and may be a safe therapeutic option for most patients with HIV.

New guidelines update ART choices, endorse long-acting injectables, refine infant feeding advice, and prioritise shorter TB preventive regimens.

In this open-label trial with a 2-by-4 factorial design, we randomly assigned children with HIV who had first-line treatment failure to receive second-line therapy with tenofovir alafenamide fumarate ...

Pseudoscience has recently re-emerged in the U.S. While much of it concerns vaccines, an "oldie" is again making the rounds: HIV is neither the cause nor the sole cause of AIDS. This nonsense has been ...

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...